focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Tekmar
Over £40m turnover
Five group companies!
21 locations worldwide
36 years experience
Offshore wind
Floating wind
Infrastructure
Marine Civils
Interconnectors
Telecoms
Subsea cables
Multiple bags in the making!
GLA
The 60 days period of exclusivity doesn’t mean they will need all 60 days. Could be a lot sooner than the 25 days left
Can see us all making some serious money here.
Todays contract win, working with the JV within SSE renewables, Equinor and Vargronn. 3 of the biggest players in the offshore renewable space.
£1 is only £61m penny’s to these monster energy companies. The tech ( cables ) has been patented according to RNS from awhile back. Could go crazy very quickly here
GLA
DSFLAT
My thinking exactly. Personally think we see £1 here in the short term
Any sniff of a buyout to a big company and this will fly.
61m shares in issue,
Tiny mcap
Orders worth over £20m
Another contract today for 130km or offshore cables
Offshore wind farms are going to be massive for renewables
June £20m in orders on the books for first 6 months of the year. And todays contract win. Very positive
HL showing BID STITUATION. hopefully RNS soon
Stop loss hunt didn’t work. Down to 11.50 and straight back up. Strong finish on the cards
25 days or so to wait
Could see a real push between now and 12.30 with people wanting in.
Someone buy in the background in numbers
I have been buying. Getting offered buy price to sell on a dummy
Sadly Budd will not give two f*cks about any emails sent to him. I agree he has to go. Sadly I don’t think he will.
GLA
Genflow research partner has been very busy! A very positive read this. A lot going on behind the scenes
A Project by Biotech Entrepreneur Ethan Perlstein & Magnitude
Background
One of the greatest challenges for biomedical sciences is how to slow ageing. Ageing is the major risk factor for almost all chronic diseases. And it has been estimated that one extra year of working life would increase UK GDP by 1%. Ethan Perlstein and others found that a small molecule called SMER28 was an inducer of autophagy. This earlier research used a multi-species approach to drug discovery that started with a yeast chemical modifier screen and was followed by studies in flies and human cells to further understand the mechanism of action. Subsequently, SMER28 was shown to improve models of anemia in human hematopoietic stem cells, zebrafish and mice. However, there was no known effect on Healthspan, and the target remained unknown.
Ethan identified the contract research organisation Magnitude Biosciences to investigate the efficacy of SMER28 to promote health and slow ageing, as he was familiar with how studies in the nematode C. elegans could be translatable for drug discovery, and that Magnitude Biosciences had unique capabilities and a reputation for strong data reproducibility as led by CEO David Weinkove.
Findings
Magnitude Biosciences revealed SMER28 showed toxicity at relatively low concentrations, but using their unique Automated Imaging Platform, they found a range of concentrations with a robust positive effect on Healthspan. Establishing a dose response of SMER28 also demonstrated the sensitivity of Magnitude’s technology to identify tight therapeutic windows of compound concentrations that slow ageing.
Perspective
Excitingly, the target of SMER28 was recently identified by Wrobel et al (2022) in human cells as VCP (p97). This target is well conserved in C. elegans. The ****logue CDC-48.1 has 80% identity with the human protein, opening up an exciting opportunity to further study SMER28 in vivo to determine the mechanism for slowing ageing. The C. elegans cdc-48.1 mutant can be used to validate the target, determine if the toxicity remains in the absence of the target, and if so, ID any off-target effect. This work would provide a platform to discover new molecules that would be derivatives of SMER28 that hit the desired target to slow ageing but avoid the toxicity. This new safe molecule could be used to develop therapeutics to slow ageing in humans.
2x 750,000 just through. False drop don’t be fooled into selling your shares. They’re getting desperate
Bots? I genuinely think the sp is being manipulated to fill these big orders. Hopeing people sell when they see red. My buys showing red today. All games
Money, big pharma taking a position?
Again someone is loading up here. 2x2m a few weeks ago and now this today. Good times ahead.
GLA
Have been thinking about the new patent application plus the other one already submitted earlier in the year. I know these need approval and I’m sure they will get approved going off the company video on proactive. Company has stated doing everything in the correct manner, no short cuts. Surely even at this stage Genflow must be seen as a huge takeover option for big pharma. There’s far too much going on here for it not to be.
When the patents get approved this will propel the company even further away from competitors.
Just my thoughts. Would be really good to hear other people’s off the board too.
GLA